CLC Bio has completed a specialised immuno-informatics solution that is fully customised to fit into Symphogen's Symplex technology.
Symplex technology is designed for high throughput identification of antibodies with diversity and specificity customised to a particular therapeutic application.
CLC Bio has developed a CLC Main Workbench plug-in, which is designed to optimise the end-to-end workflow and analysis pipeline when working with the large number of antibodies retrieved during the Symplex process.
Allan Jensen, director of antibody discovery at Symphogen, said: 'When investigating the diversity and complexity of disease-relevant antibody repertories from human donors, speed and quality are essential.
'Thus, the faster we can go through our initial bio-informatics workflow and identify a diverse panel of complementary antibodies of interest, the earlier we can compose the optimal recombinant polyclonal antibody drug lead candidate to advance into development.
'CLC Bio has fully integrated the workflow by automating all the steps in the downstream bio-informatics analysis process.
'This has accelerated the research process by eliminating tedious and complicated manual procedures and removes the overhead of keeping third-party software running and updated - and in turn it provides a high quality and robust workflow.'
